Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT00868608 (Clinical Trial / inotuzumab ozogamycin / CMC-544)

Study Title
Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma (NCT00868608)

Trial Description
The purpose of this study is to evaluate the efficacy of inotuzumab ozogamicin (CMC-544) in subjects with indolent Non-Hodgkins lymphoma (NHL) that is refractory or has relapsed after multiple therapies including rituximab or radioimmunotherapy. The investigational drug will be given to subjects with indolent NHL by intravenous infusion at a dose of 1.8 mg/m2, every 4 weeks.

This trial is sponsored by UCB Pharma/Pfitzer.  [1]

Study Data

  • Condition: Lymphoma
  • Interventions:
    • Drugs used in this trial
      • Inotuzumab Ozogamicin (CMC-544)
  • Phase: II
  • Enrollment: 81
  • Start: July 2009
  • Completion: June 2013
  • Last verified: July, 2013

Study Schematic 

NCT00868608 (Clinical Trial / inotuzumab ozogamycin / CMC-544)

Click here to Return to Drug map


Last Editorial review: July 30, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar